jcm-logo

Journal Browser

Journal Browser

Clinical Research and Personalized Medicine in Inflammatory Bowel Disease

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 959

Special Issue Editors


E-Mail Website
Guest Editor
Department of Medical and Surgical Sciences, Digestive Diseases Centre (CEMAD), Policlinico Universitario "A. Gemelli" Foundation, IRCCS, 00168 Rome, Italy
Interests: gastroenterology; inflammatory bowel diseases; gut microbiota; cardiovascular risk in IBD; GI endoscopy

E-Mail Website
Guest Editor
Internal Medicine and Gastroenterology Department, IRCCS Fondazione Policlinico Gemelli, Catholic University of Rome, 00168 Rome, Italy
Interests: gastroenterology; inflammatory bowel diseases; gut microbiota; GI endoscopy; gut immunology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to submit your manuscript to the Journal of Clinical Medicine for consideration for a Special Issue entitled “Clinical Research and Personalized Medicine in Inflammatory Bowel Disease".

Over the last several decades, advances in clinical research, immunology, and precision medicine have transformed our understanding of the pathogenesis of IBD, leading to more targeted and individualized treatment approaches. However, despite this progress, many questions remain unanswered regarding disease progression, therapeutic responses, and patient-specific factors influencing outcomes.

This Special Issue, “Clinical Research and Personalized Medicine in Inflammatory Bowel Disease”, will provide a comprehensive platform for innovative research aimed at improving our ability to tailor treatments to individual patients. With the rise in genomics, microbiome analysis, and artificial intelligence in healthcare, we are at a pivotal moment in the evolution of IBD management. This Special Issue will explore novel diagnostic tools, predictive biomarkers, patient stratification strategies, and innovative therapeutic interventions, bridging the gap between research and clinical applications.

We invite original research articles and reviews that contribute to this growing field. Topics of interest include, but are not limited to, the following:

  • Advances in the genetic and molecular mechanisms underlying IBD;
  • The role of the gut microbiome in disease progression and therapy response;
  • Biomarker-driven approaches to personalized treatment strategies;
  • Machine learning and AI applications in predicting treatment outcomes;
  • Novel biologics, small molecules, and combination therapies for IBD;
  • Patient-reported outcomes and real-world data in personalized medicine.

We look forward to receiving your valuable contributions and advancing the science behind personalized medicine in IBD together.

Dr. Alfredo Papa
Dr. Loris Riccardo Lopetuso
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory bowel disease (IBD)
  • personalized medicine
  • precision medicine
  • Crohn’s disease
  • ulcerative colitis
  • targeted therapy
  • artificial intelligence

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 539 KiB  
Article
Resilience and Self-Care in Patients with Inflammatory Bowel Disease: A Multicentre Cross-Sectional Study in Outpatient Settings
by Daniele Napolitano, Mattia Bozzetti, Alessio Lo Cascio, Giuseppe De Stefano, Nicoletta Orgiana, Loris Riccardo Lopetuso, Antonio Maria D’Onofrio, Giovanni Camardese, Alfredo Papa, Franco Scaldaferri, Antonello Cocchieri and Davide Bartoli
J. Clin. Med. 2025, 14(11), 3868; https://doi.org/10.3390/jcm14113868 - 30 May 2025
Viewed by 852
Abstract
Background/Objectives: Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), significantly affects patients’ quality of life. Resilience and self-care are vital for disease management, yet their relationship with IBD remains underexplored. This study investigates how self-care behaviours influence resilience in [...] Read more.
Background/Objectives: Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), significantly affects patients’ quality of life. Resilience and self-care are vital for disease management, yet their relationship with IBD remains underexplored. This study investigates how self-care behaviours influence resilience in patients with IBD, taking into account sociodemographic and clinical factors. Methods: This was a multicentre observational study. Data were collected during routine outpatient visits between April and June 2024. Participants (≥18 years) with an IBD diagnosis for at least 12 months were recruited. Data were collected using validated instruments, including the Connor-Davidson Resilience Scale (CD-RISC-25), the Self-Care of Chronic Illness Inventory (SC-CII), and sociodemographic and clinical questionnaires. Disease activity was assessed using the Mayo Score (UC) and the Harvey–Bradshaw Index (CD). Descriptive, correlational, and regression analyses explored variable relationships. This study was conducted as part of the N-ECCO Research Grant initiative. Results: A total of 401 participants (CD: 196, UC: 205) were enrolled, with equal gender distribution (50.1% male). The descriptive analysis of self-care levels showed a mean score of 72.6 (SD = 12.5) for self-care maintenance, 81.0 (SD = 18.2) for self-care monitoring, and 70.5 (SD = 18.4) for self-care management. The UC patients had higher self-care management scores than the CD patients (p = 0.002). The median resilience score was 45, and self-care management positively predicted resilience (β = 0.041, p < 0.001). Disease severity negatively affected resilience and self-care, particularly in severe cases (β = −8.334, p < 0.001). The females reported higher resilience and self-care monitoring scores than the men. Conclusions: Resilience and self-care are interrelated and crucial in IBD management. Enhancing resilience through personalised nursing interventions and integrating psychological and educational support may improve self-care and clinical outcomes. Full article
Show Figures

Figure 1

Back to TopTop